July 2- EOD–> Midday edition

I wanted to follow up on the discussion of yesterday less with an analysis of the potential dance partners for ONXX but more in terms of where do we go from here. Obviously the speculation in mid and small caps space is who will be next. This list could encompass just about every company but […]

July 1- EOD

Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than my article this morning. 1. In my article I tried to cover the companies that I thought had the most compelling reasons to be interested […]

Week’s Option Activity (6/24~6/28)

The following stocks had notable activity in their options during the past week: $SGEN (6/24): 3,000 SEP 35.0 strike Calls were sold (stock at $30.30) for a credit of 1.20 and 1.25 (1,200 @ 1.25, 1,800 @ 1.20) or $366,000. At the (approximate) same time, 3,000 SEP 25.0/20.0 strike Put spreads were bought for 1.15 […]

June 25- EOD

It was an odd day in the market as it was strong but many biotechs appeared weak. I am going to focus exclusively today on SGEN as we got more details and I have been digging into the weeds to try and get a handle on what this means. So there were more details on […]

June 24- EOD

There was a lot that happened last week that I will slowly get to go through it the next week but on a big picture macro front, I actually think this is going to end up generating some nice values for long term investors. When biotechs get hit in the macro mess it is not […]

June 3- EOD

Happy mid-ASCO (although most of the data is already presented). Some interesting ASCO and, surprisingly, non-ASCO stories. 1. I added to my SGEN position today (at $33.67). It has been under pressure recently and I’ve been looking to add over the summer in anticipation of HL data at ASH. I am intimately aware of the […]

May 29- EOD

It seemed like a nice selloff in biotech today. There were the occasional winners (INFI) but for the most part it was a sea of red today. The summer months can be difficult times for biotechs but they have been quite resilient and these sell-offs have ended up being good buying opportunities. 1. I want […]

Week’s Option Activity (5/6~5/10)

The following stocks had notable activity in their options during the past week: $HOLX (5/7/13): 3,900 DEC 22.0/18.0 strike Strangles were purchased for a net debit of 2.05 or a total cost of $799,500. DEC 22.0 Calls were bought for 1.00 and DEC 18.0 strike Puts were bought for 1.05 (stock at $20.66). Buyer makes […]

Preview of ASCO2013 Take One

With the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) rapidly approaching, we want to take the time to present our highlights of the meeting. This is one of the largest medical meetings investors focus upon in the biotech and healthcare sectors. Before we get into this, we do have some overarching […]

What we’re looking for at ASH 2012

On Monday, November 5th, abstracts submitted to 2012 Annual Meeting of the American Society of Hematology (ASH) Annual Meeting will be published online. A time has not been released, but we have heard they will be released at 10AM Eastern time. Below are some comments on companies we expect to have a present at the […]

SGEN – Update on Seattle Genetics

A series of recent moves by Seattle Genetics is positioning the company to capitalize on its current success to build for future growth. As previously mentioned in our last report, Seattle Genetics is on track to start three Phase III studies for Adcetris in the front line setting this year: Hodgkin’s Lymphoma (HL), Mature T-cell […]

SGEN – 2011 Q4 Report: Adcetris Launch On Track

SGEN 2011 Q4 Report: Adcetris Launch On Track 2/13/2012 Well, that certainly didn’t seem to go well. On a day when Regeneron (NASDAQ:REGN) saw its stock jump 12% on better than expected sales guidance of its macular degeneration treatment Eylea, Seattle Genetics (NASDAQ:SGEN) stock tumbled 5% the next day for only meeting quarterly revenue estimates. […]

ASH Stock Preview

2011 ASH Stock Preview It’s the end of the year, which can mean only one thing- the American Society of Hematology Convention is coming up! ASH is the year’s largest meeting for researchers and investors interested in hematology, or blood cancers. This year’s convention will be held from December 9th through 12th in sunny San […]

Antibody Engineering Wars

Therapeutic antibodies have been in use for decades now, becoming a mainstay for the treatment of cancer and inflammatory diseases. The molecules have evolved quickly through scientific advancements from simple mouse antibodies to complex humanized antibody-drug conjugates. Rapid growth in this category has grabbed Big Pharma’s attention, shifting its focus away from traditional small molecule […]

Seattle Genetics Consolidating Its Strong ADC Position

Today, Seattle Genetics announced a partnership with Abbott to develop a drug against a single target using their antibody-drug-conjugate (ADC) technology. Abbott will pay $8 million upfront and up to $200 million in milestones as well as royalties on worldwide sales, if any. This deal comes quickly after news of the expansion of an ADC […]

Seattle Genetics and Immunogen: Fabless Biotechs?

Jason Chew The results are in and it appears Seattle Genetics’ Antibody Drug Conjugate (ADC) technology does indeed work after all- not that it should be a surprise to anyone following the company. Results released early Monday morning showed 75% of relapsed or refractory Hodgkin’s Lymphoma (HL) patients taking the drug Brentuximab Vendotin, or as […]